About: Xenon Pharmaceuticals Inc., a neuroscience-focused biopharmaceutical company, engages in the discovery, development, and delivery of therapeutics to treat patients with neurological and psychiatric disorders. Its product candidates include Azetukalner, a novel, potent Kv7 potassium channel opener which is in Phase 3 clinical development for the treatment of epilepsy, including focal onset seizures, and primary generalized tonic-clonic seizures, as well as neuropsychiatric disorders, such as major depressive disorder and bipolar depression. In addition, the company's Phase 1 Single Ascending Dose/Multiple Ascending Dose products include XEN1701 targeting the sodium channel and XEN1120 targeting the Kv7 potassium channel for the treatment of pain. The company has a license and collaboration agreement with Neurocrine Biosciences, Inc. for the development of NBI-921355, a Nav1.2/1.6 sodium channel inhibitor that is in Phase 1 clinical trials for the treatment of certain types of epilepsy. Xenon Pharmaceuticals Inc. was incorporated in 1996 and is headquartered in Burnaby, Canada.
Sector: Healthcare
Industry: Biotechnology
Latest price: $37.41 (-0.35%)
XENE NASDAQ Xenon Pharmaceuticals Inc
Xenon Pharmaceuticals Inc share price
XENE price activity
Last Price
$37.410
Change (24hr)
-0.13 USD (0.35%)
Volume
1.11M
Volume (4w avg)
-
Open
$37.54
Day Range
$36.84 - $38.12
Previous Close
$37.54
Last Trade
30 Oct, 8:00 pm GMT+0
Delayed
30 Oct, 8:00 pm GMT+0
XENE price performance
Delayed
30 Oct, 8:00 pm GMT+0
XENE Market Signals